Table 3.
Tumor volume change between the baseline and C4 MRI for the development, retrospective independent testing, and prospective blinded testing groups.
Groups | Tumor volume change (cm3) | Percentage change (%) | ||||
---|---|---|---|---|---|---|
pCR patients | Non-pCR patients | p | pCR patients | Non-pCR patients | p | |
Development | − 11 ± 13 | − 16 ± 21 | 0.11 | − 89 ± 10 | − 69 ± 28 | < 0.01 |
Testing (R) | − 12 ± 8 | − 24 ± 56 | 0.40 | − 92 ± 14 | − 70 ± 26 | < 0.01 |
Testing (P) | − 13 ± 16 | − 13 ± 18 | 0.93 | − 89 ± 26 | − 61 ± 30 | < 0.01 |
pCR pathological complete response, Development patients for model training and validation, Testing (R) retrospective independent testing, Testing (P) prospective blinded testing.